Compare NUTX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | SPRY |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | NUTX | SPRY |
|---|---|---|
| Price | $100.73 | $9.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $252.50 | $35.00 |
| AVG Volume (30 Days) | 207.7K | ★ 1.7M |
| Earning Date | 11-19-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 17.98 | N/A |
| Revenue | ★ $981,195,633.00 | $142,772,000.00 |
| Revenue This Year | $108.77 | N/A |
| Revenue Next Year | $3.69 | $126.72 |
| P/E Ratio | $5.56 | ★ N/A |
| Revenue Growth | 236.03 | ★ 5459.66 |
| 52 Week Low | $40.67 | $6.66 |
| 52 Week High | $193.07 | $18.90 |
| Indicator | NUTX | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 31.57 | 43.87 |
| Support Level | $98.59 | $9.60 |
| Resistance Level | $165.00 | $10.74 |
| Average True Range (ATR) | 12.49 | 0.54 |
| MACD | -5.96 | -0.10 |
| Stochastic Oscillator | 11.55 | 25.01 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.